# AKY15-HK-301_NEPA Study

Source: https://onco.cc/trials/nct03386617/  
OnCo record `nct03386617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Netupitant and palonosetron in Breast cancer, run by Chinese University of Hong Kong, active and no longer recruiting.

## Summary

AKY15-HK-301_NEPA Study is a phase 2 interventional study registered as NCT03386617 by Chinese University of Hong Kong, with 55 participants planned, started 2018-02-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: NEPA. Conditions recorded: Breast Cancer.

Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03386617
- Phase: 2
- Setting: Open Label Single Arm Study for NEPA [Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron] in Hong Kong Oncology Patients Receiving (Neo)-Adjuvant Chemotherapy Treatment Consists of Adriamycin and Cyclophosphamide for Breast Cancer
- Sponsor: Chinese University of Hong Kong
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT03386617: https://clinicaltrials.gov/study/NCT03386617

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Netupitant and palonosetron](https://onco.cc/drugs/netupitant-palonosetron/)

---
JSON: https://onco.cc/api/v1/entities/nct03386617.json